New combo therapy aims to keep early lung cancer at bay

NCT ID NCT03446547

First seen Apr 20, 2026 · Last updated May 12, 2026 · Updated 3 times

Summary

This study tested whether adding the drug durvalumab after precise radiation therapy (SBRT) helps people with early-stage lung cancer stay cancer-free longer. About 106 patients with stage I non-small cell lung cancer who could not have surgery were randomly assigned to receive either durvalumab every 4 weeks for a year or just follow-up. The main goal was to see if the drug delays cancer progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC, STAGE I are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dept of Oncology

    Tampere, Finland

  • Dept of Oncology

    Vaasa, Finland

  • Dept of Oncology

    Oslo, Norway

  • Dept of Oncology

    Trondheim, Norway

  • Dept of Oncology

    Stockholm, Sweden

  • Dept of pulmonary medicine

    Tromsø, Norway

  • Dept of pulmonary medicine

    Gävle, Sweden

  • Dept of pulmonary medicine

    Linköping, Sweden

  • Dept of pulmonary medicine

    Lund, Sweden

  • Dept. of Oncology

    Gothenburg, Sweden

  • Dept. of Oncology

    Umeå, Sweden

  • Helsinki

    Helsinki, Finland

  • Sunderbyn

    Luleå, Sweden

  • Turku

    Turku, Finland

  • Ålesund

    Ålesund, Norway

Conditions

Explore the condition pages connected to this study.